OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Neumayer Discusses the POWER PIINC Trial

December 18th 2013

Leigh A. Neumayer, MD, discusses the POWER PIINC trial, a study to measure the preoperative window of endocrine therapy.

Dr. Turner Discusses the PALOMA-3 Trial

December 17th 2013

Nicholas Turner, PhD, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.

Dr. Landgren on Combinations in Newly Diagnosed Myeloma

December 16th 2013

C. Ola Landgren, MD, PhD, from the National Cancer Institute, discusses a phase II trial that explored the combination of carfilzomib, lenalidomide, and dexamethasone followed by maintenance lenalidomide in patients with newly diagnosed multiple myeloma.

Dr. Durie on a More Sensitive Automated Flow Cytometry MRD Test

December 16th 2013

Brian G.M. Durie, MD, chairman, International Myeloma Foundation, hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses a more sensitive automated flow cytometry minimal residual disease (MRD) test.

Dr. Mateos on Elderly Patients With Newly Diagnosed MM

December 16th 2013

MarÃa-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.

Dr. Berenson on a Study of Pomalidomide in R/R Myeloma

December 13th 2013

James R. Berenson, MD, discusses a phase I/II study looking at pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. The study was presented at the 2013 ASH Meeting.

Dr. Belani Discusses Treating NSCLC with CO-1686

December 6th 2013

Chandra P. Belani, MD, discusses CO-1686, which is currently being studied for the treatment of non-small cell lung cancer.

Dr. Galsky on the Role of Ipilimumab in Bladder Cancer

December 5th 2013

Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses the role of ipilimumab in bladder cancer.

Dr. McTiernan on Biomarkers in Breast Cancer

December 4th 2013

Anne McTiernan, MD, PhD, research professor of epidemiology, University of Washington, member, Fred Hutchinson Cancer Research Center, discusses the biomarkers that are associated with poor prognosis in patients with breast cancer.

Dr. Fuchs on Aspirin for the Treatment of Colorectal Cancer

December 3rd 2013

Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses the use of aspirin for the prevention and treatment of colorectal cancer.

Dr. Brose Describes the DECISION Trial

December 3rd 2013

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.

Dr. Pal on Sequencing Nivolumab in RCC

December 2nd 2013

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing nivolumab in the treatment of renal cell carcinoma.

Dr. Finn on AMG900 in Breast Cancer

December 2nd 2013

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses using AMG900 to treat breast cancer.

Dr. Levis on the Challenges of Treating FLT3-ITD AML

November 27th 2013

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia (AML).

Dr. Kelly on Selecting Therapy for Patients with CRPC

November 27th 2013

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.

Dr. Keedy on Resistance in Patients With GIST

November 26th 2013

Vicki Keedy, MD, assistant professor of medicine, clinical director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses resistance in patients with GIST.

Dr. Herbst on PD-1 Inhibitors in Lung Cancer

November 26th 2013

Roy S. Herbst, MD, PhD, discusses the sequencing possibilities of anti-PD-1 agents in treating patients with lung cancer.

Dr. Tempero on Pancreatic Cancer Immunotherapies

November 25th 2013

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the outlook for immunotherapies in pancreatic cancer.

Dr. Balar on Immunotherapy in Bladder Cancer

November 25th 2013

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the potential of immunotherapy agents as treatment for bladder cancer.

Dr. Rapoport on Hyponatremia in Patients With Cancer

November 22nd 2013

Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, discusses hyponatremia in patients with cancer.